trending Market Intelligence /marketintelligence/en/news-insights/trending/2-QOnosTXJ98ciDK4D4RfA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Creso Pharma to acquire Colombian medicinal cannabis company

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Creso Pharma to acquire Colombian medicinal cannabis company

Creso Pharma Ltd proposed to acquire Kunna Canada Ltd. and its medicinal cannabis unit Kunna SAS for up to US$7.15 million in shares.

The consideration shares will be issued based on an assumed market price of A$1.10 per Creso share. The deal also includes up to US$1 million in performance shares priced A$1.10 apiece and a US$250,000 exclusivity option payment. The exclusivity fee is expected to be paid Jan. 2, 2018.

The performance shares will convert into Creso ordinary shares on a 1-for-1 basis when Kunna SAS successfully cultivates and sells 100 kilograms of cannabis from its operations within 18 months of settlement of the acquisition.

The shares will be issued subject to shareholder and regulatory approvals.

The proposed acquisition makes Creso the only Australian-listed medicinal cannabis company with direct exposure to the Colombian market, with a better foothold in the wider Latin American medicinal cannabis market, the company said.

The agreement is subject to Creso completing due diligence on Kunna, regulatory and shareholder approvals and Kunna acquiring cultivation license, all of which must be satisfied by April 30, 2018.

The deal is expected to close by March-April 2018.